eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.

IF 2.5 3区医学 Q3 ONCOLOGY

World Journal of Surgical Oncology Pub Date : 2025-04-01 DOI:10.1186/s12957-025-03746-w

Shuang Hou, Hao Tang, Zhikun Dong, Wence Zhou

{"title":"eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.","authors":"Shuang Hou, Hao Tang, Zhikun Dong, Wence Zhou","doi":"10.1186/s12957-025-03746-w","DOIUrl":null,"url":null,"abstract":"Background: Gastric carcinoma (GC) is a leading cause of cancer-related deaths, with a dire prognosis for advanced stages. The molecular mechanisms underlying GC progression are not fully understood, necessitating research into novel biomarkers and therapeutic targets. This study investigates the role of eukaryotic translation initiation factor 6 (eIF6) in GC, focusing on its potential as a prognostic indicator and its impact on tumor biology.Methods: We analyzed eIF6 expression in GC tissues using data from TCGA and GEO databases. Experiments included western blot, IHC staining, and cell culture assays on GC cell lines to evaluate the effect of eIF6 on cell proliferation, invasion, and apoptosis. Statistical analyses were performed using Student's t-tests and ANOVA, with significance set at p < 0.05.Results: eIF6 was found to be significantly overexpressed in GC tissues, associated with advanced tumor stage and poor patient survival. Functional assays demonstrated that eIF6 knockdown inhibits GC cell proliferation and invasion while promoting apoptosis. Transcriptomic analysis linked eIF6 to the PI3K/AKT pathway, a critical regulator in cancer.Conclusions: eIF6's overexpression in GC suggests its role in tumor progression, highlighting its potential as a therapeutic target. The study provides a foundation for developing targeted therapies against eIF6 and emphasizes the need for further research into its regulatory mechanisms in GC.","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"113"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963666/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-03746-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gastric carcinoma (GC) is a leading cause of cancer-related deaths, with a dire prognosis for advanced stages. The molecular mechanisms underlying GC progression are not fully understood, necessitating research into novel biomarkers and therapeutic targets. This study investigates the role of eukaryotic translation initiation factor 6 (eIF6) in GC, focusing on its potential as a prognostic indicator and its impact on tumor biology.

Methods: We analyzed eIF6 expression in GC tissues using data from TCGA and GEO databases. Experiments included western blot, IHC staining, and cell culture assays on GC cell lines to evaluate the effect of eIF6 on cell proliferation, invasion, and apoptosis. Statistical analyses were performed using Student's t-tests and ANOVA, with significance set at p < 0.05.

Results: eIF6 was found to be significantly overexpressed in GC tissues, associated with advanced tumor stage and poor patient survival. Functional assays demonstrated that eIF6 knockdown inhibits GC cell proliferation and invasion while promoting apoptosis. Transcriptomic analysis linked eIF6 to the PI3K/AKT pathway, a critical regulator in cancer.

Conclusions: eIF6's overexpression in GC suggests its role in tumor progression, highlighting its potential as a therapeutic target. The study provides a foundation for developing targeted therapies against eIF6 and emphasizes the need for further research into its regulatory mechanisms in GC.

查看原文本刊更多论文

eIF6：通过PI3K/AKT通路调节的胃癌治疗靶点

背景：胃癌（GC）是癌症相关死亡的主要原因，晚期预后恶劣。GC进展的分子机制尚不完全清楚，因此需要研究新的生物标志物和治疗靶点。本研究探讨真核翻译起始因子6 （eIF6）在胃癌中的作用，重点探讨其作为预后指标的潜力及其对肿瘤生物学的影响。方法：利用TCGA和GEO数据库的数据分析eIF6在GC组织中的表达。实验采用western blot、免疫组化染色、细胞培养等方法观察eIF6对GC细胞系细胞增殖、侵袭和凋亡的影响。采用学生t检验和方差分析进行统计学分析，显著性设置为p。结果：eIF6在胃癌组织中显著过表达，与肿瘤分期晚期和患者生存率低相关。功能实验表明，eIF6敲低抑制GC细胞的增殖和侵袭，同时促进细胞凋亡。转录组学分析将eIF6与PI3K/AKT通路联系起来，PI3K/AKT通路是癌症的关键调节因子。结论：eIF6在胃癌中的过表达表明其在肿瘤进展中的作用，突出了其作为治疗靶点的潜力。该研究为开发针对eIF6的靶向治疗提供了基础，并强调了进一步研究其在GC中的调控机制的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Surgical Oncology ONCOLOGY-SURGERY

CiteScore

4.70

自引率

15.60%

发文量

362

审稿时长

3 months

期刊介绍： World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics. Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.